Insulinoma differential diagnosis: Difference between revisions

	Insulinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Insulinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Insulinoma differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Insulinoma differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Insulinoma differential diagnosis
CDC on Insulinoma differential diagnosis
Insulinoma differential diagnosis in the news
Blogs on Insulinoma differential diagnosis
Directions to Hospitals Treating Insulinoma
Risk calculators and risk factors for Insulinoma differential diagnosis

← Older edit Newer edit →

VisualWikitext

Revision as of 15:49, 16 October 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

Insulinoma must be differentiated from other diseases that cause features of hypoglycemia like altered mental status/confusion, profuse sweating and visual disturbances (blurring/diplopia). These are classified on the basis of laboratory findings into exogenous insulin, oral hypoglycemic agents (e.g. sulphonylureas), nesidioblastosis, insulin autoimmune hypoglycemia.

Differentiating insulinoma from other Diseases

Insulinoma must be differentiated from other diseases that cause features of hypoglycemia. These are classified on the basis of laboratory findings.

Differentials for Hypoglycemia on the basis of Laboratory findings:^[1]:

Diagnoses	Laboratory Findings differentiating among causes of Hypoglycemia
Diagnoses	S.Glucose (mg/dL)	C Peptide (pmol/L)	S.Insulin (μU/mL)	S.Proinsulin (pmol/L)	S. Beta hydroxybutyrate	Glucose increase after glucagon(mg/dL)	Oral Hypoglycemic agent	Antibodies to Insulin
Normal/Fasting	<55	<200	<3	<5	>2.7	<25	-	-
Exogenous Insulin	<55	<200	>>3	<5	≤2.7	>25	-	-
Insulinoma/Nesidioblastosis/PGPH^†	<55	≥200	≥3	≥5	≤2.7	>25	-	-
Insulin autoimmune hypoglycemia	<55	>>200^‡	>>3	>>5^‡	≤2.7	>25	-	+
Oral hypoglycemic agent	<55	≥200	≥3	≥5	≤2.7	>25	+	-
IGF¤	<55	<200	<3	<5	≤2.7	>25	-	-

† PGPH= Post Gastric Bypass Hypoglycemia,
‡ Free C-peptide and proinsulin concentrations are low
¤ IGF= Insulin Growth Factor, Increased pro-IGF-2, free IGF-2, IGF-2/IGF-1 ratio

Differentiating hypoglycemia from other diseases that cause autonomic hyperactivity symptoms (tachycardia, hypertension):


Disease	Clinical Manifestation					Investigations
	Symptoms				Signs
	Tachycardia	Fever	Sweating	Headache	Signs
Anxiety disorders	+	-	+	+	Patient looks irritable Rapid pulse and may be irregular	Normal investigations
Pheochromocytoma	+	+	+	+	Tachycardia Strong rapid pulse High pulse pressure	Plasma fractionated metanephrines, 24-hour urinary fractionated metanephrines, catecholamines.^[2] Computed tomography: Radiological evaluation should follow lab tests to locate site of the tumour.^[3]
Arrhythmia	+	-	-	-	Irregular pulse	ECG changes according to the cause
Hyperthyroidism	+	+	+	+	Hyperactive deep tendon reflexes Thyromegaly Exophthalmus	Level of thyroid-stimulating hormone (TSH) Levels of T4 and/or T3 in the blood Antibodies such as anti-TSH-receptor antibodies in Graves' disease

References

↑ Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.
↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. PMID 11903030.
↑ Bravo EL (1991). "Pheochromocytoma: new concepts and future trends". Kidney Int. 40 (3): 544–56. PMID 1787652.

Template:WH Template:WS

[pmid19088155-1] Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER; et al. (2009). "Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 94 (3): 709–28. doi:10.1210/jc.2008-1410. PMID 19088155.

[pmid11903030-2] Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. PMID 11903030.

[pmid1787652-3] Bravo EL (1991). "Pheochromocytoma: new concepts and future trends". Kidney Int. 40 (3): 544–56. PMID 1787652.

[1]

[2]

[3]

@@ Line 7: / Line 7: @@
 ==Differentiating insulinoma from other Diseases==
-*Insulinoma must be differentiated from other diseases that cause features of [[hypoglycemia]]. These are classified on the basis of [[laboratory]] findings.
+Insulinoma must be differentiated from other diseases that cause features of [[hypoglycemia]]. These are classified on the basis of [[laboratory]] findings.
 '''Differentials for [[Hypoglycemia]] on the basis of Laboratory findings:'''<ref name="pmid19088155">{{cite journal| author=Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER et al.| title=Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. | journal=J Clin Endocrinol Metab | year= 2009 | volume= 94 | issue= 3 | pages= 709-28 | pmid=19088155 | doi=10.1210/jc.2008-1410 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19088155  }} </ref>: